Ex­elix­is drug fails PhI­II lung can­cer tri­al with Cabome­tyx and Tecen­triq com­bo

Ex­elix­is’ tri­al of Cabome­tyx and Tecen­triq for pa­tients with metasta­t­ic non-small cell lung can­cer failed to meet its goal of ex­tend­ing over­all sur­vival com­pared to chemother­a­py.

The com­pa­ny shared the fail­ure in a brief press re­lease Thurs­day af­ter­noon. It said it will share oth­er, sec­ondary out­comes at the tri­al at a fu­ture med­ical meet­ing.

The 366 pa­tients in the tri­al re­ceived Ex­elix­is’ drug Cabome­tyx in com­bi­na­tion with Roche’s Tecen­triq or do­c­etax­el. All of the pa­tients had been treat­ed pre­vi­ous­ly with an­ti-PD-1 or PD-L1 drugs that failed to stop their can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER